ArticleDrug delivery2022
Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy.
Article in Drug delivery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- The Effects of Omega-3 Polyunsaturated Fatty Acids on Breast Cancer as a Preventive Measure or as an Adjunct to Conventional Treatments.Nutrients · 2023Pooled it
- Nano-Immunotherapy Targeting TAMs: Precisely Regulating TAMs to Reverse Immunosuppressive TME.International journal of nanomedicine · 2026Review
- Advances in Oral Drug Delivery Systems for Natural Polyunsaturated Fatty Acids: Enhancing Bioavailability and Therapeutic Potential.Pharmaceutics · 2025Review
- Advanced Pharmaceutical Nanotechnologies Applied for Chinese Herbal Medicines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Embracing cancer immunotherapy with manganese particles.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Advancements in Nanoemulsion-Based Drug Delivery Across Different Administration Routes.Pharmaceutics · 2025Review
- Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects.Experimental hematology & oncology · 2025Review
- Scavenger receptor class B member 1 promotes lung cancer growth and metastasis through enhanced twist family BHLH transcription factor 1 signalingCytoJournal · 2025Article
- The Current Status, Hotspots, and Development Trends of Nanoemulsions: A Comprehensive Bibliometric Review.International journal of nanomedicine · 2025Review
- Advances in cell membrane-based biomimetic nanodelivery systems for natural products.Drug delivery · 2024Review
- Biomineralized apoferritin nanoparticles delivering dihydroartemisinin and calcium for synergistic breast cancer therapy.Scientific reports · 2024Article
- Solubilization techniques used for poorly water-soluble drugs.Acta pharmaceutica Sinica. B · 2024Review
- Review
- Lipid-Based Nanocarriers: Bridging Diagnosis and Cancer Therapy.Pharmaceutics · 2024Review
- Recent advances in mitochondria-targeting theranostic agents.Exploration (Beijing, China) · 2024Review
- Progress in reeducating tumor-associated macrophages in tumor microenvironment.Discover oncology · 2024Review
- Better together: nanoscale co-delivery systems of therapeutic agents for high-performance cancer therapy.Frontiers in pharmacology · 2024Review
- Polysaccharide dextran-based conjugate for selective co-delivery of two synergistic drugs docetaxel and docosahexaenoic acid to tumor cells.Drug delivery · 2023Article
- Effect and mechanism of paclitaxel loaded on magnetic FeDrug delivery · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is one of the most common types of cancer in female patients with high morbidity and mortality. Multi-drug chemotherapy has significant advantages in the treatment of malignant tumors, especially in reducing drug toxicity, increasing drug sensitivity and reducing drug resistance. The objective of this research is to fabricate lipid nanoemulsions (LNs) for the co-delivery of PTX and docosahexaenoic acid (DHA) with folic acid (FA) decorating (PTX/DHA-FA-LNs), and investigate the anti-tumor activity of the PTX/DHA-FA-LNs against breast cancer both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.